Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06027957 | CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia | completed | Phase 1 | 18 | Vinmec Research Institute of Stem Cell and Gene TechnologyOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT04169321 | Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | completed | Phase 1 | 13 | Cytosite Biopharma Inc.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT04970992 | A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Da Zen Theranostics IncINDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05390814 | [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma(FLUDALOC) | completed | Phase 1 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05950334 | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | completed | Phase 1 | 20 | Fate TherapeuticsINDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03039114 | Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) | completed | Phase 1 | 26 | Incyte CorporationINDUSTRY | 6 | Aug 21, 2025 | clinicaltrials |
| NCT03424122 | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | completed | Phase 1 | 50 | Incyte CorporationINDUSTRY | 3 | Aug 21, 2025 | clinicaltrials |
| NCT04210219 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 85 | Janssen Research & Development, LLCINDUSTRY | 7 | Aug 21, 2025 | clinicaltrials |
| NCT04657224 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 75 | Janssen Research & Development, LLCINDUSTRY | 12 | Aug 21, 2025 | clinicaltrials |
| NCT04876092 | A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL | completed | Phase 1 | 45 | Janssen Research & Development, LLCINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT01660607 | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | completed | Phase 1 / Phase 2 | 68 | Stanford UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03828292 | An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments | completed | Phase 1 | 15 | GlaxoSmithKlineINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04260217 | APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia(MAPLE-1) | completed | Phase 1 | 46 | Ascentage Pharma Group Inc.INDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT01771107 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 41 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT03739619 | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 3 | Emory UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03331341 | Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07102706 | Phase I Trial of GR1803 Injection in Patients With RRMM | completed | Phase 1 / Phase 2 | 76 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT01711671 | A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03013218 | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | completed | Phase 1 | 174 | ALX Oncology Inc.INDUSTRY | 2 | Aug 1, 2025 | clinicaltrials |
| NCT03548207 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma(CARTITUDE-1) | completed | Phase 1 / Phase 2 | 126 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT01864018 | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | completed | Phase 1 / Phase 2 | 87 | Mayo ClinicOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04813653 | Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells | completed | Phase 1 | 3 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04473911 | Haplo Peripheral Blood Sct In GVHD Prevention | completed | Phase 1 | 25 | Zachariah Michael DeFilippOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05011097 | A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 20 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT01051635 | A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2025 | clinicaltrials |
| NCT03884556 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | completed | Phase 1 | 56 | Trishula Therapeutics, Inc.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT02546167 | CART-BCMA Cells for Multiple Myeloma | completed | Phase 1 | 25 | University of PennsylvaniaOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT01995669 | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT02446964 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia | completed | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT03900598 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 226 | Janssen Research & Development, LLCINDUSTRY | 12 | Jun 22, 2025 | clinicaltrials |
| NCT03770260 | Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment | completed | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03742258 | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT01290302 | Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza | completed | Phase 1 | 38 | American Regent, Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02303392 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | completed | Phase 1 | 34 | Jennifer WoyachOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT00112827 | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | City of Hope Medical CenterOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05290155 | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies | completed | Phase 1 | 14 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT03448393 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | completed | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2025 | clinicaltrials |
| NCT02975687 | CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia | completed | Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03870945 | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) | completed | Phase 1 | 12 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT04696432 | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | completed | Phase 1 | 7 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT02519452 | A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 6 | May 23, 2025 | clinicaltrials |
| NCT04317885 | A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | completed | Phase 1 | 25 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04655677 | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | completed | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03472573 | Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT04240808 | Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 10 | University of Colorado, DenverOTHER | 1 | May 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 26, 2025source: clinicaltrials